Vasil'tsev Ia S, Karpov R S, Markov V A, Varvarenko V I, Kun V I
Kardiologiia. 1986 Aug;26(8):58-63.
The effect of intracoronary streptokinase administration (31 patients), verapamil treatment (23 patients) and conventional therapy (27 patients) on the size of the affected area was examined in patients with acute myocardial infarction (MI). Streptokinase was administered in a dose of 250,000-500,000 IU within the first 3 to 20 hours of myocardial infarction, and verapamil, 360 to 400 mg, daily within the first 5 to 12 hours of the attack. The occluded coronary artery was recanalized in response to streptokinase administration in 21 patients. Serial measurements of CPK activity and serum myoglobin levels, and electrocardiographic precordial cartograms demonstrated a reduction in MI size following streptokinase administration. Verapamil had no basic effect on the final size of myocardial lesion, although it improved somewhat the clinical course of the disease.
在急性心肌梗死(MI)患者中,研究了冠状动脉内注射链激酶(31例患者)、维拉帕米治疗(23例患者)和传统治疗(27例患者)对梗死面积大小的影响。链激酶在心肌梗死的最初3至20小时内以250,000 - 500,000国际单位的剂量给药,维拉帕米在发作后的最初5至12小时内每天给药360至400毫克。21例患者在注射链激酶后闭塞的冠状动脉再通。对肌酸磷酸激酶(CPK)活性和血清肌红蛋白水平进行系列测量,以及心电图胸前导联图显示,注射链激酶后心肌梗死面积减小。维拉帕米对心肌病变的最终大小没有根本影响,尽管它在一定程度上改善了疾病的临床进程。